Brief: Medivir's MIV-711 For Osteoarthritis Study Shows Reduction In Pain
28/02/2022 09:44
Feb 28 (Reuters) - Medivir AB MVIRb.ST :
* A SUBGROUP ANALYSIS OF MEDIVIR'S PHASE II STUDY OF MIV-711
FOR
OSTEOARTHRITIS SHOWS STATISTICALLY SIGNIFICANT REDUCTION IN OA
PAIN
Source text for Eikon: ID:nWkrbVG1jp
Further company coverage: MVIRb.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))